FS reports advisory boards and lecture fees from Novartis (STAND clinical trial adjudication committee chair), Bristol Meyers Squibb (Celgene Cop), Vertex Pharmaceuticals, Bluebird Bio, Chiesi, Roche, Silence Therapeutics, Agios Pharmaceuticals (IDMC committee RISE UP, ENERGIZE, studies, and ACTIVATE studies), Pharmacosmos (IDMC committee) and Pfizer. EW reports research funding to institution from AbbVie, Amgen, AstraZeneca, BeiGene, Celgene, CSL Behring, Gilead, Janssen, Novartis, Roche, Sanofi, Sobi and Takeda. AM reports being a member of advisory boards for Novartis, Bristol Meyers Squibb, Bluebird Bio and Vertex Pharmaceuticals; and research funding and travel support from Agios Pharmaceuticals. All competing interests are outside the present work.